A Hemoglobin-Based Multifunctional Therapeutic: Polynitroxylated Pegylated Hemoglobin

Artificial Organs

Volumn 36, Issue 2, 2012, Pages 215-220

  Hsia, Carleton Jen Chang ^a   Ma, Li ^b  

^a Synzyme Technologies Inc   (United States)

^b GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

Hemoglobin; Hemoglobin based oxygen carrier; Nitroxide; Oxidative stress; Poly(ethylene) glycol

Indexed keywords

BRAIN; DISEASE CONTROL; ETHYLENE; OXIDATIVE STRESS; RESUSCITATION;

ANTI-OXIDATIVE STRESS; HAEMOGLOBINS; HEME IRON; HEMOGLOBIN-BASED OXYGEN CARRIERS; HEMORRHAGIC SHOCK; NITROXIDES; PEGYLATED HEMOGLOBINS; REDOX COUPLING; SICKLE CELL DISEASE; TRAUMATIC BRAIN INJURIES;

HEMOGLOBIN;

HEMOGLOBIN; MACROGOL; POLYNITROXYLATED PEGYLATED HEMOGLOBIN; RINGER LACTATE SOLUTION; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE CHEST SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; BLOOD TRANSFUSION; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN PERFUSION; CHEMICAL STRUCTURE; FLUID RESUSCITATION; HEMODYNAMICS; HEMORRHAGIC SHOCK; HUMAN; HYPOTENSION; HYPOVOLEMIA; INTENSIVE CARE; INTRACRANIAL PRESSURE; MEAN ARTERIAL PRESSURE; NEUROPROTECTION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROTEIN MODIFICATION; REPERFUSION INJURY; STROKE; THERMOSTABILITY; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; VASCULARIZATION;

ANIMALIA;

EID: 84857077489     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2011.01307.x     Document Type: Article

References (27)

1. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299:2304-12.
2. FDA /NIH Workshop. "Hemoglobin based oxygen carriers: current status and future directions, " Bethesda, Maryland, Wednesday, April 29-30, 2008. Available at: Accessed June 29, 2011.
3. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol 1999;17:545-49.
4. Sloan EP. The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents. Intensive Care Med 2003;29:347-9.
5. Gould SA, Moore EE, Hoyt DB, etal. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002;195:445-52.
6. Jacobs E. Clinical update: hemopure(r)-a room temperature stable hemoglobin oxygen carrier. Anasthesiol Intensivmed Notfallmed Schmerzther 2001;36(Suppl. 2):S121-2.
7. Hsia JC, Song DL, Er SS, etal. Pharmacokinetic studies in the rat on a o-raffinose polymerized human hemoglobin. Biomater Artif Cells Immobilization Biotechnol 1992;20:587-95.
8. Burhop K. The development of a second-generation, designer, recombinant hemoglobin. Artif Oxygen Carrier 2005;12:127-34.
9. Alayash AI. Oxygen therapeutics: can we tame haemoglobin? Nat Rev Drug Discov 2004;3:152-9.
10. Ma L, Hsia CJC. Taming the hemoglobin: therapeutic and imaging applications of redox coupled nitroxide and hemoglobin. Xth International Symposium on Blood Substitutes, Providence, RI, USA, June 12-15, 2005.
11. Krishna MC, Ma L, Samuni A, Trimble CE, Mitchell JB, Hsia CJC. Superoxide dismutase- and catalase-mimetic activity of a polynitroxyl hemoglobin (PNH). Artif Cells Blood Substit Immobil Biotechnol 1996;24:369.
12. Buehler PW, Haney CR, Gulati A, Ma L, Hsia CJ. Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radic Biol Med 2004;37:124-35.
13. D'Agnillo F, Chang TM. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat Biotechnol 1998;16:667-71.
14. Simoni J, Simoni G, Martinez-Zaguilan R, etal. Improved blood substitute: evaluation of its effects on human endothelial cells. ASAIO J 1998;44:M356-67.
15. Winslow RM. The role of hemoglobin oxygen affinity in oxygen transport at high altitude. Respir Physiol Neurobiol 2007;158:121-7.
16. Kawaguchi AT, Nakai K, Fukumoto D, Yamano M, Haida M, Tsukada H. S-nitrosylated pegylated hemoglobin reduces the size of cerebral infarction in rats. Artif Organs 2009;33:183-8.
17. Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008;117:1982-90.
18. Rodriguez C, Vitturi DA, He J, etal. Sodium nitrite therapy attenuates hypertensive effects of HBOC-201 via nitrite reduction. Biochem J 2009;422:423-32.
19. Spinella PC, Carroll CL, Staff I, etal. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care 2009;13:R151.
20. Stoyanovsky DA, Kapralov A, Huang Z, etal. Unusual peroxidase activity of polynitroxylated pegylated hemoglobin: elimination of H(2)O(2) coupled with intramolecular oxidation of nitroxides. Biochem Biophys Res Commun 2010;399:139-43.
21. Beckman JD, Belcher JD, Vineyard JV, etal. Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am J Physiol Heart Circ Physiol 2009;297:H1243-53.
22. Shellington DK, Du L, Wu X, etal. Polynitroxylated pegylated hemoglobin: a novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice. Crit Care Med 2011;39:494-505.
23. Blasiole B, Bayir H, Vagni V, etal. Resuscitation of experimental traumatic brain injury and hemorrhagic shock in mice: acute effects of polynitroxylated pegylated hemoglobin and 100% oxygen. Crit Care Med 2010;38(Suppl.):39. Abstract 145.
24. Koehler RC, Cao S, Zhanf J, Kwansa H. Effect of cell-free hemoglobin on the cerebral circulation. XIIth ISBS meeting in Parma, Italy, August 25-27, 2009.
25. Klaus JA, Kibler KK, Abuchowski A, Koehler RC. Early treatment of transient focal cerebral ischemia with bovine pegylated carboxy hemoglobin transfusion. Artif Cells Blood Substit Immobil Biotechnol 2010;38:223-9.
26. Hsu LL, Champion HC, Campbell-Lee SA, etal. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007;109:3088-9.
27. Hsia CJC, Ma L. PNPH-a therapeutic for inadequate blood flow and superoxide, nitric oxide dependent vascular dysfunctions. XIIth ISBS Meeting in Parma, Italy, August 25-27, 2009.